Facial Injectables Market Analysis By Product (Collagen, Hyaluronic Acid, Botulinum Toxin Type A, Calcium Hydroxylapatite, Polymer Fillers), By Application (Aesthetics, Therapeutics), By Region, And Segment Forecasts, 2014 - 2025

The global facial injectables market is expected to reach USD 17.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to exhibit lucrative growth during the forecast period, owing to advancements in facial rejuvenation procedures and increasing importance of medical aesthetics across the globe.
Development in products & procedures, as well as change in patient demographics is helping dermatologists and physicians treat multiple facial areas. These advancements help dermatologists or physicians develop customized treatment for patients and facilitate use of combination products to obtain better outcomes. All these factors are expected to assist in the market growth over the forecast period. Augmented products such as Botulinum Toxin Type A (BoNTA) and Hyaluronic Acid (HA) fillers are used in combination to improve outcomes, especially in the lower face procedures. HA fillers are mostly preferred by physicians due to their better acceptance (few instances of hypersensitivity reactions), biodegradable nature, & high viscosity as well as for the longevity they provide to the restored volume.
Minimally invasive surgery, an advanced medical technology, is used for facial rejuvenation, endoscopy, laparoscopy, arthroscopy and other procedures. This procedure is gaining popularity over time owing to faster recovery, low instances of postsurgery infections, lower pain, reduced scarring, and high accuracy & maximum benefits. For instance, as per International Society of Aesthetic Plastic Surgery (ISAPS), more than 20.0 million surgical and nonsurgical cosmetic procedures were performed worldwide in 2014.The number of HA-based surgeries performed in 2014 was 2,690,633, which increased to 2,865,086 in 2015, which is thereby expected to contribute to the growth of this space over the forecast period.
Further key findings from the study suggest:
‧ The hyaluronic acid segment held a lucrative share in 2016 and is expected to grow at a significant rate over the forecast period owing to increasing preference for combination treatments such as hyaluronic acid with BoNTA.
‧ The BoNTA segment is anticipated to witness the fastest growth over the forecast period due to increasing application in aesthetics and therapeutics
‧ The aesthetics segment is expected to dominate the market during the forecast period owing to increasing expenditure on aesthetic procedures coupled with rising beauty consciousness among consumers
‧ North America is expected to dominate the facial injectables market over the forecast period due to growing geriatric population base, increasing consumer disposable income, and surge in number of facial procedures in the region
‧ Some of the key players in facial injectables market are ALLERGAN; Ipsen; Merz Pharma; Suneva Medical, Inc.; Medytox, Inc.; Sinclair Pharma; Bloomage BioTechnology Corporation Limited; Anika Therapeutics, Inc.; Prollenium Medical Technologies Inc.; and Galderma S.A.

Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.1.1. Purchased database
1.1.2. GVR’s internal database
1.2. Data Analysis
1.3. Market Formulation & Validation
1.4. Approaches for Market Estimation
1.4.1. Approach 1: Commodity flow approach
1.4.2. Approach 2: Bottom-up approach
Chapter 2. Executive Summary
2.1. Market Snapshot, 2016
Chapter 3. Facial Injectables Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Size and Growth Prospects
3.3. Market Driver Analysis
3.3.1. Increasing beauty consciousness among consumers
3.3.2. Growing geriatric population
3.4. Market Restraint Analysis
3.4.1. Side effects associated with certain facial injectables
3.5. Penetration & Growth Prospect Mapping
3.6. SWOT Analysis, by Factor
3.6.1. Political
3.6.2. Economic
3.6.3. Technological
3.7. Industry Analysis - Porter’s
Chapter 4. Facial Injectables Market: Product Estimates & Trend Analysis
4.1. Product Movement Analysis & Market Share, 2016 & 2025
4.2. Market Size Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following product:
4.2.1. Collagen
4.2.1.1. Collagen market estimates and forecasts, 2014 - 2025
4.2.2. Hyaluronic Acid
4.2.2.1. Hyaluronic acid market estimates and forecasts, 2014 - 2025
4.2.3. Botulinum Toxin Type A
4.2.3.1. Botulinum toxin type A market estimates and forecasts, 2014 - 2025
4.2.4. Calcium Hydroxylapatite
4.2.4.1. Calcium hydroxylaptite market estimates and forecasts, 2014 - 2025
4.2.5. Polymer Fillers
4.2.5.1. Polymer fillers market estimates and forecasts, 2014 - 2025
4.2.5.2. Polymethylmethacrylate beads
4.2.5.2.1. Polymethylmethacrylate beads market estimates and forecasts, 2014 - 2025
4.2.5.3. Poly-L-lactic Acid
4.2.5.3.1. Poly-L-lactic Acid market estimates and forecasts, 2014 - 2025
Chapter 5. Facial Injectables Market: Application Estimates & Trend Analysis
5.1. Application Movement Analysis & Market Share, 2016 & 2025
5.2. Market Size Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following application:
5.2.1. Aesthetics
5.2.2. Therapeutics
Chapter 6. Facial Injectables Market: Regional Estimates & Trend Analysis
6.1. Regional Movement Analysis & Market Share, 2016 & 2025
6.2. North America
6.2.1. U.S.
6.2.1.1. U.S. revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.2.1.2. U.S. revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.2.2. Canada
6.2.2.1. Canada revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.2.2.2. Canada revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.3. Europe
6.3.1. UK
6.3.1.1. UK revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.3.1.2. UK revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.3.2. Germany
6.3.2.1. Germany revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.3.2.2. Germany revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.4. Asia Pacific
6.4.1. Japan
6.4.1.1. Japan revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.1.2. Japan revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.4.2. China
6.4.2.1. China revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.2.2. China revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.4.3. India
6.4.3.1. India revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.3.2. India revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Brazil revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5.1.2. Brazil revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.5.2. Mexico
6.5.2.1. Mexico revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5.2.2. Mexico revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
6.6. MEA
6.6.1. South Africa
6.6.1.1. South Africa revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.6.1.2. South Africa revenue estimates and forecasts, by application, 2014 - 2025 (USD Million)
Chapter 7. Competitive Landscape`
7.1. Strategy Framework
7.2. Company Profiles
7.2.1. Allergan plc
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.2. Ipsen
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Merz Pharma Gmbh & Co.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.4. Suneva Medical, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Medytox, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial Performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Sinclair Pharma
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Bloomage BioTechnology
7.2.7.1. Company overview
7.2.7.2. Financial Performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Anika Therapeutics, Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Prollenium Medical Technologies Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Galderma S.A.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives